纳武单抗联合伊匹单抗治疗伴肉瘤样去分化的乳头状肾细胞癌的快速深度反应 - Suppr

Suppr

超能文献

Rapid Deep Responses With Nivolumab Plus Ipilimumab in Papillary Renal Cell Carcinoma With Sarcomatoid Dedifferentiation.

作者信息

Schvartsman Gustavo, Carneiro Andre P C D, Filippi Renee Z, Rao Priya, Msaouel Pavlos

机构信息

Hospital Israelita Albert Einstein, São Paulo, Brazil.

出版信息

Clin Genitourin Cancer. 2019 Aug;17(4):315-318. doi: 10.1016/j.clgc.2019.05.023. Epub 2019 May 25.

DOI:10.1016/j.clgc.2019.05.023

PMID:31213412

Abstract

摘要

相似文献

Rapid Deep Responses With Nivolumab Plus Ipilimumab in Papillary Renal Cell Carcinoma With Sarcomatoid Dedifferentiation.

Clin Genitourin Cancer. 2019 Aug;17(4):315-318. doi: 10.1016/j.clgc.2019.05.023. Epub 2019 May 25.

Safe and effective use of nivolumab plus ipilimumab in a patient with metastatic clear-cell renal cell carcinoma with sarcomatoid dedifferentiation and end stage renal disease on hemodialysis.

Cancer Treat Res Commun. 2021;27:100349. doi: 10.1016/j.ctarc.2021.100349. Epub 2021 Mar 10.

Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma.

Jpn J Clin Oncol. 2021 Apr 1;51(4):646-653. doi: 10.1093/jjco/hyaa229.

Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma.

Int Urol Nephrol. 2022 Jan;54(1):47-54. doi: 10.1007/s11255-021-03042-y. Epub 2021 Oct 26.

Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial.

Nat Commun. 2025 Jan 10;16(1):578. doi: 10.1038/s41467-024-55642-8.

Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma.

Expert Opin Biol Ther. 2018 Sep;18(9):947-957. doi: 10.1080/14712598.2018.1513485. Epub 2018 Aug 30.

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.

N Engl J Med. 2023 May 11;388(19):1767-1778. doi: 10.1056/NEJMoa2212851.

Salvage ipilimumab associated with a significant response in sarcomatoid renal cell carcinoma.

J Immunother Cancer. 2020 Feb;8(1). doi: 10.1136/jitc-2020-000584.

Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab.

Clin Genitourin Cancer. 2024 Dec;22(6):102181. doi: 10.1016/j.clgc.2024.102181. Epub 2024 Jul 31.

Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial.

Ann Oncol. 2025 Apr 1. doi: 10.1016/j.annonc.2025.03.016.

引用本文的文献

2024 CUA-KCRNC Expert Report: Management of non-clear cell renal cell carcinoma.

Can Urol Assoc J. 2024 Nov;18(11):E371-E386. doi: 10.5489/cuaj.9041.

Renal Cell Carcinoma of Variant Histology: Biology and Therapies.

Hematol Oncol Clin North Am. 2023 Oct;37(5):977-992. doi: 10.1016/j.hoc.2023.04.019. Epub 2023 May 25.

Safe and effective use of nivolumab plus ipilimumab in a patient with metastatic clear-cell renal cell carcinoma with sarcomatoid dedifferentiation and end stage renal disease on hemodialysis.

Cancer Treat Res Commun. 2021;27:100349. doi: 10.1016/j.ctarc.2021.100349. Epub 2021 Mar 10.

Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn't, and What the Future Holds.

Clin Genitourin Cancer. 2021 Apr;19(2):103-116. doi: 10.1016/j.clgc.2020.11.005. Epub 2020 Dec 2.

Sarcomatoid renal cell carcinoma: biology, natural history and management.

Nat Rev Urol. 2020 Dec;17(12):659-678. doi: 10.1038/s41585-020-00382-9. Epub 2020 Oct 13.

Complete response of renal cell carcinoma with an inferior vena cava tumor thrombus and lung metastases after treatment with nivolumab plus ipilimumab.

Int Cancer Conf J. 2020 Mar 13;9(2):88-91. doi: 10.1007/s13691-020-00403-9. eCollection 2020 Apr.

本文引用的文献

Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes.

Clin Genitourin Cancer. 2019 Jun;17(3):e678-e688. doi: 10.1016/j.clgc.2019.03.018. Epub 2019 Apr 1.

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.

J Immunother Cancer. 2017 Nov 21;5(1):95. doi: 10.1186/s40425-017-0300-z.

Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.

Cancer. 2017 Dec 15;123(24):4823-4831. doi: 10.1002/cncr.30937. Epub 2017 Aug 22.

Rapid Response to Nivolumab in a Patient With Sarcomatoid Transformation of Chromophobe Renal Cell Carcinoma.

Clin Genitourin Cancer. 2017 Dec;15(6):e1127-e1130. doi: 10.1016/j.clgc.2017.05.028. Epub 2017 Jun 3.

Immune Check Point Inhibition in Sarcomatoid Renal Cell Carcinoma: A New Treatment Paradigm.

Clin Genitourin Cancer. 2017 Oct;15(5):e897-e901. doi: 10.1016/j.clgc.2017.05.018. Epub 2017 May 25.

Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras.

J Urol. 2017 Sep;198(3):530-537. doi: 10.1016/j.juro.2017.04.067. Epub 2017 Apr 11.

A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors.

J Mol Diagn. 2017 Mar;19(2):255-264. doi: 10.1016/j.jmoldx.2016.09.011. Epub 2016 Dec 23.

Abscopal effect in metastatic renal cell carcinoma.

Acta Clin Belg. 2017 Aug;72(4):245-249. doi: 10.1080/17843286.2016.1201614. Epub 2016 Jul 18.

The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours.

Eur Urol. 2016 Jul;70(1):93-105. doi: 10.1016/j.eururo.2016.02.029. Epub 2016 Feb 28.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验